期刊
PANCREAS
卷 47, 期 9, 页码 1123-1129出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPA.0000000000001150
关键词
PD-1; PD-L1; PD-L2; immune checkpoint; T-cell markers; neuroendocrine tumor
资金
- Gitta and Saul Kurlat Fund for Neuroendocrine Tumor Research
- Meador Fund for Neuroendocrine Tumor Research
- Jane Dybowski Fund of Neuroendocrine Cancer
- McIntyre Family Fund for Neuroendocrine Tumor Research
- Lipson Family Fund
- Goldhirsh-Yellin Foundation Fund for Neuroendocrine Tumor Research
- Murphy Family Fund for Carcinoid Tumor Research
Objectives The immune environment and the potential for neuroendocrine tumors (NETs) to respond to immune checkpoint inhibitors remain largely unexplored. We assessed immune checkpoint marker expression, lymphocytic infiltrate, and associated mutational profiles in a cohort of small intestine and pancreatic NETs. Methods We assessed expression of PDCD1 (PD-1), CD274 (PD-L1), and PDCD1LG2 (PD-L2) in archival tissue from 64 small intestine (SINETs) and 31 pancreatic NETs (pNET). We additionally assessed T-cell infiltrates, categorizing T-cell subsets based on expression of the T-cell markers CD3, CD8, CD45RO (PTPRC), or FOXP3. Finally, we explored associations between immune checkpoint marker expression, lymphocytic infiltrate, and tumor mutational profiles. Results Expression of PD-1 or PD-L1 in small intestine or pancreatic NET was rare, whereas expression of PD-L2 was common in both NET subtypes. T-cell infiltrates were more abundant in pNET than in SINET. We found no clear associations between immune checkpoint marker expression, immune infiltrates, and specific mutational profile within each tumor type. Conclusions Our findings provide an initial assessment of the immune environment of well-differentiated NETs. Further studies to define the immunologic differences between pNET and SINET, as well as the role of PD-L2 in these tumors, are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据